Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer | Zendy

Ruichuan Chen | Zendy; Jasper H. N. Yik | Zendy; Qiao Jing Lew | Zendy; ShengHao Chao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer

Author(s) -

Ruichuan Chen,

Jasper H. N. Yik,

Qiao Jing Lew,

ShengHao Chao

Publication year - 2014

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2014/232870

Subject(s) - brd4 , p tefb , rna polymerase ii , bromodomain , transcription (linguistics) , microbiology and biotechnology , cancer research , chemistry , biology , gene expression , promoter , biochemistry , gene , epigenetics , linguistics , philosophy

Bromodomain-containing protein 4 (Brd4) and hexamethylene bisacetamide (HMBA) inducible protein 1 (HEXIM1) are two opposing regulators of the positive transcription elongation factor b (P-TEFb), which is the master modulator of RNA polymerase II during transcriptional elongation. While Brd4 recruits P-TEFb to promoter-proximal chromatins to activate transcription, HEXIM1 sequesters P-TEFb into an inactive complex containing the 7SK small nuclear RNA. Besides regulating P-TEFb's transcriptional activity, recent evidence demonstrates that both Brd4 and HEXIM1 also play novel roles in cell cycle progression and tumorigenesis. Here we will discuss the current knowledge on Brd4 and HEXIM1 and their implication as novel therapeutic options against cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research